{"result": {"id": "31b339ba-253b-47b6-bca1-e9d56f0d4e66", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"ASCVD and Lipid Management Community\",\n    \"summary\": \"The community is centered around Atherosclerotic Cardiovascular Disease (ASCVD) and its management through lipid control, involving key entities such as LDL-C, PCSK9 inhibitors, and the Chinese guidelines for lipid management. These entities are interconnected through relationships that highlight the importance of LDL-C in ASCVD risk assessment, the role of PCSK9 inhibitors in lipid-lowering treatments, and the application of the Chinese guidelines for ASCVD prevention. The community's focus on ASCVD, a leading cause of mortality, underscores its significant impact on public health.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The high impact severity rating reflects the critical role of ASCVD management in preventing cardiovascular mortality and morbidity, supported by extensive relationships and data.\",\n    \"findings\": [\n        {\n            \"summary\": \"Central Role of LDL-C in ASCVD Risk Assessment\",\n            \"explanation\": \"LDL-C is identified as a primary biomarker and intervention target for ASCVD, with its levels being crucial for risk stratification and management. The relationship between ASCVD and LDL-C underscores the importance of monitoring and controlling LDL-C to mitigate cardiovascular risks. [Data: Relationships (1689)]\"\n        },\n        {\n            \"summary\": \"PCSK9 Inhibitors as a Key Therapeutic Option\",\n            \"explanation\": \"PCSK9 inhibitors, including novel options like MK?0616, play a significant role in lipid-lowering treatments, especially for high-risk ASCVD patients. These inhibitors work by enhancing the liver's ability to remove LDL-C from the bloodstream, offering a vital therapeutic avenue. [Data: Entities (2077, 4572); Relationships (4848)]\"\n        },\n        {\n            \"summary\": \"Chinese Guidelines for Lipid Management\",\n            \"explanation\": \"The 2023 Chinese guidelines for lipid management provide a framework for ASCVD risk assessment and prevention, emphasizing the use of domestic population data. These guidelines are pivotal in shaping treatment protocols and risk stratification methods. [Data: Entities (4529); Relationships (4747)]\"\n        },\n        {\n            \"summary\": \"Mixed Hyperlipidemia and ASCVD Risk\",\n            \"explanation\": \"Mixed hyperlipidemia significantly increases the risk of ASCVD by elevating both cholesterol and triglycerides, necessitating comprehensive management strategies. This condition highlights the complexity of lipid abnormalities in cardiovascular health. [Data: Entities (4516); Relationships (4716)]\"\n        },\n        {\n            \"summary\": \"Innovative Treatments and Technologies\",\n            \"explanation\": \"Emerging treatments like Evinacumab and technologies such as CRISPR-Cas gene editing offer new possibilities for lipid management and ASCVD treatment. These innovations represent the cutting edge of cardiovascular disease prevention and therapy. [Data: Entities (4573, 4575); Relationships (4850, 4854)]\"\n        }\n    ]\n}", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752168571, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 604, "prompt_tokens": 5547, "total_tokens": 6151, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2112}, "prompt_cache_hit_tokens": 2112, "prompt_cache_miss_tokens": 3435}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        },\n        {\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        },\n        {\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        },\n        {\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }\n    ]\n}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\r\n2040,ASCVD,\"**Atherosclerotic Cardiovascular Disease (ASCVD)** is a cardiovascular condition characterized by the buildup of arterial plaque, leading to the hardening and narrowing of arteries. This condition significantly increases the risk of serious cardiovascular events, including heart attacks, strokes, and other complications. ASCVD is the leading cause of death among urban and rural residents in China, accounting for over 40% of fatalities.  \n\nASCVD risk is assessed through stratification methods, categorizing individuals as low, medium, or high risk based on factors such as smoking, low HDL-C (high-density lipoprotein cholesterol), age, hypertension, and dyslipidemia. This risk assessment is particularly important for Chinese adults, guiding management strategies that include lifestyle interventions (e.g., diet, exercise) and medication, such as statins and PCSK9 inhibitors for high-risk patients.  \n\nThe condition is closely linked to lipid abnormalities, with lipid-lowering treatments being a primary therapeutic approach. Key biomarkers like ApoB (apolipoprotein B) and LDL-C (low-density lipoprotein cholesterol) are used to predict ASCVD risk and determine target values for patients, especially those with comorbidities like hypertension and diabetes. Regular lipid monitoring is essential for prevention and treatment.  \n\nASCVD is also referred to as **Arteriosclerotic Cardiovascular Disease**, emphasizing its association with cholesterol levels and overall cardiovascular health. While terminology may vary slightly, the core definition remains consistent: a progressive disease driven by plaque accumulation, necessitating proactive risk assessment and targeted therapies to mitigate adverse outcomes.  \n\nIn summary, ASCVD is a major global health concern, requiring comprehensive risk evaluation, lipid management, and tailored interventions to reduce morbidity and mortality.\",49\r\n4516,MIXED HYPERLIPIDEMIA,\"**MIXED HYPERLIPIDEMIA**  \n\nMixed hyperlipidemia is a metabolic disorder characterized by the concurrent elevation of both cholesterol and triglycerides in the blood. This condition is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) due to the combined effects of high cholesterol and triglyceride levels. Management typically requires a combination of pharmacological therapies, as single-agent treatments may not adequately address both lipid abnormalities. The disorder underscores the importance of comprehensive lipid-lowering strategies to mitigate cardiovascular risks.  \n\nThe two provided descriptions align in their definition of mixed hyperlipidemia as a dual elevation of cholesterol and triglycerides, as well as its clinical implications for ASCVD risk. Both also emphasize the necessity of combination drug therapy for effective management, reinforcing the complexity of treating this condition. The summary consolidates these points into a coherent overview without contradictions.\",8\r\n3582,冠状动脉旁路移植术,\"冠状动脉旁路移植术（Coronary Artery Bypass Grafting, CABG），也称为冠状动脉搭桥手术，是一种用于治疗严重动脉粥样硬化性心血管疾病（ASCVD）或冠心病的手术方法。该手术通过从患者身体其他部位（如胸壁或腿部）取一段健康的血管，将其移植到冠状动脉狭窄或阻塞的部位，以绕过病变区域，恢复心肌的正常血液供应。冠状动脉旁路移植术适用于多支血管病变、左主干病变或药物治疗效果不佳的患者，能够有效缓解心绞痛症状，改善心脏功能，并降低心肌梗死的风险。该手术是冠心病治疗的重要手段之一，尤其适用于病情复杂或严重的病例。\",2\r\n4529,中国血脂管理指南（2023 年）,\"Chinese guidelines for lipid management, providing ASCVD risk assessment methods based on domestic population data\",3\r\n2062,RASI,\"Renin-angiotensin system inhibitor, a class of drugs used to treat hypertension by inhibiting the renin-angiotensin system\"\"\",2\r\n2964,血脂异常的临床分类,Clinical classification system for different types of dyslipidemia,2\r\n2074,RANDOMIZED CONTROLLED TRIAL (RCT),,1\r\n2981,ARTERIOSCLEROTIC CARDIOVASCULAR DISEASE,\"Full name of ASCVD, a cardiovascular condition addressed in the lipid management guidelines\"\"\",1\r\n2983,CABG,Coronary artery bypass grafting is a surgical procedure for treating coronary artery disease,1\r\n2986,CHINESE ADULTS,\"Chinese adults are the target population for the ASCVD risk assessment and management strategies outlined.\"\"\",1\r\n3002,新发糖尿病,\"New-onset diabetes, a potential long-term risk associated with high-dose statin use\"\"\",1\r\n4524,SCORE CARDIOVASCULAR RISK SCALE,\"A risk assessment tool proposed by European dyslipidemia treatment guidelines for evaluating cardiovascular disease risk\"\"\",1\r\n4525,CANADIAN CARDIOVASCULAR LIFE EXPECTANCY MODEL,\"A model used internationally for cardiovascular disease risk assessment\"\"\",1\r\n4526,CORONARY ARTERY CALCIUM SCORE,\"A scoring system used in cardiovascular disease risk assessment\"\"\",1\r\n4527,US POOLED COHORT EQUATIONS,\"A risk assessment tool used internationally for cardiovascular disease risk evaluation\"\"\",1\r\n4528,METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE,\"A condition correlated with insulin resistance and high TG levels\"\"\",1\r\n4531,急性冠状动脉综合征,\"Acute coronary syndrome, a severe ASCVD event used for risk stratification\"\"\",1\r\n4532,经皮冠状动脉介入治疗,\"Percutaneous coronary intervention, a procedure for ASCVD management\"\"\",1\r\n2984,PCI,Percutaneous coronary intervention is a minimally invasive procedure to treat coronary artery disease,1\r\n4534,高敏C反应蛋白,\"High-sensitivity C-reactive protein (hs-CRP) is a biomarker for inflammation, with levels ≥2.0 mg/L indicating higher ASCVD risk\"\"\",1\r\n4535,冠状动脉钙化,\"Coronary artery calcium scoring ≥100 AU is a marker of ASCVD risk\"\"\",1\r\n4536,踝/臂血压指数,\"Ankle-brachial index (ABI) <0.9 is a marker of peripheral artery disease and ASCVD risk\"\"\",1\r\n2077,PCSK9,\"**PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9)** is a protein that plays a key role in cholesterol metabolism and is primarily targeted by inhibitors to lower low-density lipoprotein cholesterol (LDL-C) levels. These inhibitors, known as PCSK9 inhibitors, are used in lipid-lowering treatments, particularly for patients with extremely high-risk atherosclerotic cardiovascular disease (ASCVD) who cannot tolerate other cholesterol-lowering medications. By binding to PCSK9, these inhibitors prevent the degradation of LDL receptors, thereby enhancing the liver's ability to remove LDL-C from the bloodstream. PCSK9 inhibitors represent an important therapeutic option for managing elevated cholesterol levels in high-risk populations. The protein itself is a proprotein convertase, and its inhibition has been shown to significantly reduce LDL-C, contributing to improved cardiovascular outcomes. Overall, PCSK9 serves as a critical target for pharmacological interventions aimed at lowering cholesterol and mitigating cardiovascular risk.\",11\r\n4572,MK?0616,\"MK?0616 is a novel oral PCSK9 inhibitor that lowers LDL-C levels by inhibiting PCSK9 binding to LDL-R, with good efficacy and safety shown in phase 2b clinical trials>\",2\r\n4575,CRISPR?CAS,\"CRISPR-Cas is a gene editing technology that can permanently inhibit disease-causing genes, offering new possibilities for lipid-lowering therapy>\",1\r\n2044,CVD,\"CVD stands for Cardiovascular Disease, a broad term for heart and blood vessel disorders\"\"\",4\r\n4530,LDL?C,\"Low-density lipoprotein cholesterol, a primary biomarker and intervention target for lipid management\",4\r\n4533,中国成人 ASCVD 总体发病风险评估,,2\r\n2010,CHINESE JOURNAL OF RATIONAL DRUG USE,\"The *CHINESE JOURNAL OF RATIONAL DRUG USE* (中国合理用药探索) is an academic journal dedicated to research and discussions on rational drug use. It publishes studies and guidelines related to the appropriate application of medications, including topics such as the combination of antihypertensive and lipid-lowering therapies. The journal is also known by its English name, *Chinese Journal of Rational Drug Use*, and serves as the English edition of *中国合理用药探索*. Its primary focus is on advancing the understanding and implementation of rational drug use in clinical and research settings. By providing evidence-based insights and recommendations, the journal aims to promote safer and more effective medication practices. The publication caters to healthcare professionals, researchers, and policymakers interested in optimizing therapeutic outcomes through scientifically grounded approaches to drug utilization.\",4\r\n2015,中国合理用药探索,,1\r\n2065,FAMILIAL HYPERLIPIDEMIA,\"**Familial Hyperlipidemia** is an inherited genetic disorder characterized by abnormally high levels of lipids (fats) in the blood due to mutations passed down through families. This condition disrupts normal lipid metabolism, leading to elevated cholesterol and/or triglycerides, which increases the risk of early cardiovascular disease. The disorder is caused by genetic mutations that impair the body's ability to properly process and clear lipids from the bloodstream. While descriptions vary slightly in phrasing, they consistently emphasize its hereditary nature, the abnormal lipid accumulation, and its association with heightened cardiovascular risks. There are no significant contradictions in the provided descriptions—all agree that familial hyperlipidemia is a genetic condition with significant implications for heart health. Management typically involves lifestyle modifications and medications to control lipid levels and reduce cardiovascular risk.\",3\r\n2061,ARNI,\"Angiotensin receptor-neprilysin inhibitor, a class of drugs used as first-line treatment for hypertension\"\"\",2\r\n2963,血脂水平分层,\"\nClinical classification of blood lipid levels for ASCVD prevention\",2\r\n4573,EVINACUMAB,\"Evinaucmab is a monoclonal antibody targeting angiopoietin-like protein 3, which significantly reduces LDL-C levels as demonstrated in phase 3 clinical trials>\",2\r\n4576,ANGIOPOIETIN-LIKE PROTEIN 3,,1\r\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\r\n1689,ASCVD,LDL-C,\"**Comprehensive Summary of ASCVD and LDL-C:**  \n\nAtherosclerotic cardiovascular disease (ASCVD) risk assessment and management heavily rely on evaluating low-density lipoprotein cholesterol (LDL-C) levels, as LDL-C is a well-established pathogenic risk factor for ASCVD. LDL-C serves as both a primary biomarker and a key intervention target in ASCVD risk stratification and prevention.  \n\nClinical guidelines emphasize the importance of LDL-C in diagnosing dyslipidemia, a major contributor to ASCVD. Risk stratification tools incorporate LDL-C measurements to determine individualized target values for patients, ensuring tailored therapeutic approaches. Elevated LDL-C levels are strongly associated with increased ASCVD risk, making their reduction a cornerstone of preventive strategies.  \n\nMultiple descriptions highlight the critical role of LDL-C in assessing and managing ASCVD risk, reinforcing its dual function as a diagnostic marker and a modifiable treatment target. By lowering LDL-C through lifestyle modifications or pharmacotherapy, clinicians can significantly mitigate ASCVD risk.  \n\nIn summary, LDL-C is integral to ASCVD risk evaluation, target setting, and intervention, underscoring its central role in cardiovascular disease prevention and management.\",89\r\n4716,MIXED HYPERLIPIDEMIA,ASCVD,Mixed hyperlipidemia significantly increases risk of atherosclerotic cardiovascular disease,57\r\n3496,冠心病,冠状动脉旁路移植术,冠状动脉旁路移植术用于治疗冠心病,53\r\n4747,中国血脂管理指南（2023 年）,ASCVD,The guidelines provide risk stratification and treatment protocols for ASCVD prevention,52\r\n1728,ASCVD,RASI,RASI is recommended for patients with hypertension and high risk of ASCVD due to its effects on the renin-angiotensin system,51\r\n2451,ASCVD,血脂异常的临床分类,ASCVD risk is assessed through clinical classification of dyslipidemia,51\r\n1739,ASCVD,RANDOMIZED CONTROLLED TRIAL (RCT),RCT research has demonstrated that combined antihypertensive and lipid-lowering therapy is crucial for ASCVD prevention,50\r\n2480,ASCVD,ARTERIOSCLEROTIC CARDIOVASCULAR DISEASE,ARTERIOSCLEROTIC CARDIOVASCULAR DISEASE is the full form of the acronym ASCVD,50\r\n2484,ASCVD,CABG,CABG is a treatment for severe ASCVD cases,50\r\n2488,ASCVD,CHINESE ADULTS,Chinese adults are the primary group for whom ASCVD risk assessment and management strategies are designed.,50\r\n2506,ASCVD,新发糖尿病,\"While statins may increase diabetes risk, their benefits for ASCVD prevention outweigh this risk\",50\r\n4735,ASCVD,SCORE CARDIOVASCULAR RISK SCALE,ASCVD risk can be assessed using the SCORE cardiovascular risk scale,50\r\n4736,ASCVD,CANADIAN CARDIOVASCULAR LIFE EXPECTANCY MODEL,ASCVD risk can be assessed using the Canadian cardiovascular life expectancy model,50\r\n4737,ASCVD,CORONARY ARTERY CALCIUM SCORE,ASCVD risk can be assessed using the coronary artery calcium score,50\r\n4738,ASCVD,US POOLED COHORT EQUATIONS,ASCVD risk can be assessed using the US pooled cohort equations,50\r\n4742,ASCVD,METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE,This liver condition exacerbates ASCVD risk via insulin resistance pathways,50\r\n4750,ASCVD,急性冠状动脉综合征,Acute coronary syndrome is a critical manifestation of ASCVD,50\r\n4752,ASCVD,经皮冠状动脉介入治疗,PCI is a standard revascularization procedure for ASCVD,50\r\n4754,PCI,ASCVD,PCI is a treatment for ASCVD,50\r\n4756,ASCVD,高敏C反应蛋白,Elevated hs-CRP indicates inflammatory ASCVD risk,50\r\n4757,ASCVD,冠状动脉钙化,Coronary calcium scoring predicts ASCVD risk,50\r\n4759,ASCVD,踝/臂血压指数,Low ABI indicates peripheral artery disease and ASCVD risk,50\r\n1743,PCSK9,依折麦布,PCSK9 inhibitors and ezetimibe are alternative treatments for patients who cannot tolerate statins,16\r\n4848,MK?0616,PCSK9,MK?0616 is a PCSK9 inhibitor that works by blocking PCSK9's interaction with LDL-R,13\r\n4854,CRISPR?CAS,PCSK9,\"CRISPR-Cas gene editing can permanently inhibit PCSK9, offering a potential long-term solution for lipid management\",12\r\n1788,CVD,高血压患者,Hypertension patients are at risk of developing CVD if not managed properly,9\r\n4753,LDL?C,中国成人 ASCVD 总体发病风险评估,The assessment uses LDL-C levels as a key risk stratification parameter,6\r\n1664,CHINESE JOURNAL OF RATIONAL DRUG USE,中国合理用药探索,\"The **CHINESE JOURNAL OF RATIONAL DRUG USE** (中国合理用药探索) is an academic journal that publishes content in both Chinese and English. The journal is known by its Chinese name, **《中国合理用药探索》**, and its English name, **CHINESE JOURNAL OF RATIONAL DRUG USE**, which represent the same publication. It serves as a bilingual platform for scholarly research and discussions on rational drug use, catering to a diverse readership. The journal maintains a single editorial focus across both language versions, ensuring consistency in its academic contributions. This dual naming convention reflects its international reach while retaining its foundational identity in the Chinese academic community.\",5\r\n1732,SECONDARY HOSPITAL,FAMILIAL HYPERLIPIDEMIA,Cases of suspected familial hyperlipidemia require referral to secondary hospitals for confirmation,5\r\n4748,中国血脂管理指南（2023 年）,中国成人 ASCVD 总体发病风险评估,The 2023 guidelines formally recommend this assessment method for primary prevention,5\r\n1729,ARNI,RASI,\"Both ARNI and RASI are classes of drugs used to treat hypertension, with ARNI being a newer class that combines effects on the angiotensin receptor and neprilysin inhibition\",4\r\n2455,血脂水平分层,血脂异常的临床分类,Both are clinical classification systems related to blood lipid levels,4\r\n4850,EVINACUMAB,ANGIOPOIETIN-LIKE PROTEIN 3,Evinacumab targets angiopoietin-like protein 3 to reduce LDL-C levels,3\r\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            },\n            {\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }\n        ]\n    }\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nLimit the total report length to 2000 words.\n\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_d6b2504599abf4b6a0c3cc89263c84eaf1d18cde2bdc569f3e7060573de08e7a_v2"}